Stoke Therapeutics, Inc. $STOK Shares Purchased by US Bancorp DE

US Bancorp DE boosted its position in Stoke Therapeutics, Inc. (NASDAQ:STOK) by 9,743.9% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 11,222 shares of the company’s stock after purchasing an additional 11,108 shares during the quarter. US Bancorp DE’s holdings in Stoke Therapeutics were worth $75,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. XTX Topco Ltd acquired a new stake in shares of Stoke Therapeutics in the 1st quarter worth $267,000. Dauntless Investment Group LLC acquired a new stake in shares of Stoke Therapeutics during the 1st quarter worth about $190,000. Kennondale Capital Management LLC acquired a new stake in shares of Stoke Therapeutics during the 1st quarter worth about $280,000. Net Worth Advisory Group acquired a new stake in shares of Stoke Therapeutics during the 1st quarter worth about $138,000. Finally, GAMMA Investing LLC increased its position in shares of Stoke Therapeutics by 1,842.0% during the 1st quarter. GAMMA Investing LLC now owns 5,360 shares of the company’s stock worth $36,000 after purchasing an additional 5,084 shares during the last quarter.

Insider Activity at Stoke Therapeutics

In other Stoke Therapeutics news, insider Barry Ticho sold 4,504 shares of the business’s stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $12.82, for a total value of $57,741.28. Following the completion of the sale, the insider owned 16,775 shares in the company, valued at approximately $215,055.50. The trade was a 21.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, General Counsel Jonathan Allan sold 13,712 shares of the business’s stock in a transaction that occurred on Wednesday, August 13th. The shares were sold at an average price of $15.00, for a total value of $205,680.00. Following the completion of the sale, the general counsel owned 19,631 shares of the company’s stock, valued at approximately $294,465. This represents a 41.12% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 26,432 shares of company stock valued at $345,775. 9.50% of the stock is owned by company insiders.

Stoke Therapeutics Stock Up 1.6%

STOK stock opened at $18.51 on Tuesday. The business has a 50 day moving average price of $12.70 and a 200 day moving average price of $10.20. The stock has a market cap of $1.01 billion, a price-to-earnings ratio of 21.78 and a beta of 1.15. Stoke Therapeutics, Inc. has a fifty-two week low of $5.35 and a fifty-two week high of $18.60.

Stoke Therapeutics (NASDAQ:STOK) last posted its earnings results on Tuesday, August 12th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.17. The firm had revenue of $13.82 million during the quarter, compared to analysts’ expectations of $31.51 million. Stoke Therapeutics had a return on equity of 18.32% and a net margin of 26.25%. As a group, sell-side analysts anticipate that Stoke Therapeutics, Inc. will post -2.01 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on STOK shares. Chardan Capital reissued a “buy” rating and set a $24.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, August 13th. Jefferies Financial Group began coverage on Stoke Therapeutics in a research report on Friday, July 18th. They set a “buy” rating and a $30.00 price objective for the company. Cantor Fitzgerald upgraded Stoke Therapeutics to a “strong-buy” rating in a report on Wednesday, May 14th. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a research report on Tuesday, July 1st. Finally, HC Wainwright dropped their target price on Stoke Therapeutics from $47.00 to $35.00 and set a “buy” rating for the company in a research report on Wednesday, May 14th. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $25.57.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.